The board of directors of JBM (Healthcare) Limited announced that Dr. Cheng Celine Heung Kwan ("Dr. Cheng") has been appointed as an executive Director with effect from 9 March 2024. Dr. Cheng, aged 62, has around 30 years of experience in sterile and non-sterile manufacturing, quality assurance and Good Manufacturing Practice, specialising in quality management system and reengineering for pharmaceutical and biological products. She currently serves as the Chief Compliance & Technology Officer of Jacobson Pharma Corporation Limited ("Jacobson"), a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 2633) and controlled by Mr. Sum Kwong Yip, Derek, the Chairman of the Board, a non-executive Director and the controlling shareholder of the Company (as defined by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).

Dr. Cheng is primarily responsible for overseeing the quality system integrity, driving technological development and advancing the manufacturing know-how of Jacobson and its subsidiaries. She earned a Bachelor's degree in Pharmacy (with honours) and her Ph.D. in pharmacology from the University of Bradford, United Kingdom ("UK") in 1986 and 1990 respectively, and subsequently served as a post-doctoral research fellow at the University of Bradford. She also obtained a Master of Business Administration degree (with distinction) from the City University of Hong Kong in 2006.

Dr. Cheng is a registered pharmacist in both Hong Kong and the UK and is a fellow of the College of Pharmacy Practice of Hong Kong. She is a registered authorised person with the Pharmacy and Poison Board of Hong Kong (the "PPBHK") and served as a member of its various committees. She is currently a member of the Postgraduate Pharmacy Training and Development Committee and the Expert Advisory Group on Bioavailability and Bioequivalence Studies of the PPBHK.

She is also a member of the Expert Panel on the Designation of Designated Local Research Institutions at the Innovation and Technology Commission of Hong Kong. Dr. Cheng has extensive teaching experience. She was an Adjunct Associate Professor at the School of Professional and Continuing Education of the University of Hong Kong from July 2005 to June 2008 and has been an Adjunct Associate Professor at the School of Pharmacy of The Chinese University of Hong Kong since June 2001.

The Board announced that the following changes to the nomination committee of the Board (the "Nomination Committee") and the audit committee of the Board (the "Audit Committee") with effect from 9 March 2024: Mr. Yeung Kwok Chun, Harry, a non-executive Director, will be appointed as a member of the Nomination Committee; Mr. Chan Kam Chiu, Simon, an independent non-executive Director, will cease to be the chairman of the Audit Committee and will remain member of the Audit Committee; and Mr. Luk Ting Lung, Alan, an independent non-executive Director, will be appointed as the chairman of the Audit Committee.